196 related articles for article (PubMed ID: 11093793)
1. Replacement of an NH(3) by an iminoether in transplatin makes an antitumor drug from an inactive compound.
Leng M; Locker D; Giraud-Panis MJ; Schwartz A; Intini FP; Natile G; Pisano C; Boccarelli A; Giordano D; Coluccia M
Mol Pharmacol; 2000 Dec; 58(6):1525-35. PubMed ID: 11093793
[TBL] [Abstract][Full Text] [Related]
2. DNA-protein cross-linking by trans-[PtCl(2)(E-iminoether)(2)]. A concept for activation of the trans geometry in platinum antitumor complexes.
Novakova O; Kasparkova J; Malina J; Natile G; Brabec V
Nucleic Acids Res; 2003 Nov; 31(22):6450-60. PubMed ID: 14602903
[TBL] [Abstract][Full Text] [Related]
3. DNA binding by antitumor trans-[PtCl2(NH3)(thiazole)]. Protein recognition and nucleotide excision repair of monofunctional adducts.
Kasparkova J; Novakova O; Farrell N; Brabec V
Biochemistry; 2003 Jan; 42(3):792-800. PubMed ID: 12534292
[TBL] [Abstract][Full Text] [Related]
4. Recognition of DNA interstrand cross-links of cis-diamminedichloroplatinum(II) and its trans isomer by DNA-binding proteins.
Kaspárková J; Brabec V
Biochemistry; 1995 Sep; 34(38):12379-87. PubMed ID: 7547982
[TBL] [Abstract][Full Text] [Related]
5. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines.
Kasparkova J; Marini V; Najajreh Y; Gibson D; Brabec V
Biochemistry; 2003 May; 42(20):6321-32. PubMed ID: 12755637
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxicity and DNA binding mode of new platinum-iminoether derivatives with different configuration at the iminoether ligands.
Boccarelli A; Coluccia M; Intini FP; Natile G; Locker D; Leng M
Anticancer Drug Des; 1999 Jun; 14(3):253-64. PubMed ID: 10500500
[TBL] [Abstract][Full Text] [Related]
7. Chemical versatility of transplatin monofunctional adducts within multiple site-specifically platinated DNA.
Bernal-Méndez E; Boudvillain M; González-Vilchez F; Leng M
Biochemistry; 1997 Jun; 36(24):7281-7. PubMed ID: 9200676
[TBL] [Abstract][Full Text] [Related]
8. The stability of DNA intrastrand cross-links of antitumor transplatin derivative containing non-bulky methylamine ligands.
Frybortova M; Novakova O; Brabec V
J Biol Inorg Chem; 2014 Oct; 19(7):1203-8. PubMed ID: 24986778
[TBL] [Abstract][Full Text] [Related]
9. Transplatin-modified oligonucleotides as modulators of gene expression.
Giraud-Panis M; Leng M
Pharmacol Ther; 2000 Mar; 85(3):175-81. PubMed ID: 10739872
[TBL] [Abstract][Full Text] [Related]
10. The effect of antitumor trans-[PtCl2(E-iminoether)2] on B-->Z transition in DNA.
Zaludová R; Natile G; Brabec V
Anticancer Drug Des; 1997 Jun; 12(4):295-309. PubMed ID: 9199661
[TBL] [Abstract][Full Text] [Related]
11. Steric control of DNA interstrand cross-link sites of trans platinum complexes: specificity can be dictated by planar nonleaving groups.
Brabec V; Neplechova K; Kasparkova J; Farrell N
J Biol Inorg Chem; 2000 Jun; 5(3):364-8. PubMed ID: 10907747
[TBL] [Abstract][Full Text] [Related]
12. DNA interactions of antitumor trans-[PtCl2(NH3)(quinoline)].
Zákovská A; Nováková O; Balcarová Z; Bierbach U; Farrell N; Brabec V
Eur J Biochem; 1998 Jun; 254(3):547-57. PubMed ID: 9688265
[TBL] [Abstract][Full Text] [Related]
13. DNA modifications by antitumor trans-[PtCl2(E-iminoether)2].
Zaludová R; Zákovská A; Kaspárkova J; Balcarová Z; Vrána O; Coluccia M; Natile G; Brabec V
Mol Pharmacol; 1997 Sep; 52(3):354-61. PubMed ID: 9281596
[TBL] [Abstract][Full Text] [Related]
14. Conformation, protein recognition and repair of DNA interstrand and intrastrand cross-links of antitumor trans-[PtCl2(NH3)(thiazole)].
Marini V; Christofis P; Novakova O; Kasparkova J; Farrell N; Brabec V
Nucleic Acids Res; 2005; 33(18):5819-28. PubMed ID: 16237123
[TBL] [Abstract][Full Text] [Related]
15. Long range 1,4 and 1,6-interstrand cross-links formed by a trinuclear platinum complex. Minor groove preassociation affects kinetics and mechanism of cross-link formation as well as adduct structure.
Hegmans A; Berners-Price SJ; Davies MS; Thomas DS; Humphreys AS; Farrell N
J Am Chem Soc; 2004 Feb; 126(7):2166-80. PubMed ID: 14971952
[TBL] [Abstract][Full Text] [Related]
16. Platinum(II) complexes containing iminoethers: a trans platinum antitumour agent.
Coluccia M; Boccarelli A; Mariggiò MA; Cardellicchio N; Caputo P; Intini FP; Natile G
Chem Biol Interact; 1995 Dec; 98(3):251-66. PubMed ID: 8548863
[TBL] [Abstract][Full Text] [Related]
17. Intrastrand cross-links are not formed in the reaction between transplatin and native DNA: relation with the clinical inefficiency of transplatin.
Boudvillain M; Dalbiès R; Aussourd C; Leng M
Nucleic Acids Res; 1995 Jul; 23(13):2381-8. PubMed ID: 7630715
[TBL] [Abstract][Full Text] [Related]
18. Effect of geometric isomerism in dinuclear platinum antitumor complexes on DNA interstrand cross-linking.
Kaspárková J; Nováková O; Vrána O; Farrell N; Brabec V
Biochemistry; 1999 Aug; 38(34):10997-1005. PubMed ID: 10460154
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo antitumour activity and cellular pharmacological properties of new platinum-iminoether complexes with different configuration at the iminoether ligands.
Coluccia M; Nassi A; Boccarelli A; Giordano D; Cardellicchio N; Locker D; Leng M; Sivo M; Intini FP; Natile G
J Inorg Biochem; 1999 Oct; 77(1-2):31-5. PubMed ID: 10626350
[TBL] [Abstract][Full Text] [Related]
20. Platinum complexes with imino ethers or cyclic ligands mimicking imino ethers: synthesis, in vitro antitumour activity, and DNA interaction properties.
Intini FP; Boccarelli A; Francia VC; Pacifico C; Sivo MF; Natile G; Giordano D; De Rinaldis P; Coluccia M
J Biol Inorg Chem; 2004 Sep; 9(6):768-80. PubMed ID: 15241660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
